CHEN-HUA LIUHuang Y.-JYang S.-SChang C.-HYang S.-SHSIN-YUN SUNCHUN-JEN LIULiu W.-CTUNG-HUNG SUHUNG-CHIH YANGCHUN-MING HONGTAI-CHUNG TSENGPEI-JER CHENDING-SHINN CHENCHIEN-CHING HUNGJIA-HORNG KAO2020-12-292020-12-2920182045-2322https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053262755&doi=10.1038%2fs41598-018-32060-7&partnerID=40&md5=6f9d5c53a79c8319a88b99a62f5ab595https://scholars.lib.ntu.edu.tw/handle/123456789/535419Real-world data regarding the effectiveness and safety of generic sofosbuvir (SOF)-based interferon-free direct acting antiviral agents (DAAs) for patients with chronic hepatitis C virus (HCV) infection remain limited. A total of 517 chronic HCV-infected patients receiving 12 or 24 weeks of SOF-based therapies were retrospectively enrolled in 4 academic centers in Taiwan. The rate of sustained virologic response at week 12 off-therapy (SVR12) and that of treatment completion were assessed. The baseline characteristics and on-treatment HCV viral kinetics to predict SVR12 were analyzed. By evaluable population (EP) analysis, the SVR12 rate was 95.4% (95% confidence interval [CI]: 93.2–96.9%). The SVR12 was achieved in 29 of 34 patients (85.3%, 95% CI: 69.6–93.6%), 130 of 139 patients (93.5%, 95% CI: 88.2–96.6%), 119 of 124 patients (96.0%, 95% CI: 90.9–98.3%) and 215 of 220 patients (97.7%, 95% CI: 94.8–99.0%) who received SOF in combination with ribavirin (RBV), ledipasvir (LDV), daclatasvir (DCV) and velpatasvir (VEL), respectively. Of 517 patients, 514 (99.4%) completed the scheduled treatment. All 15 patients with true virologic failures were relapsers. Two decompensated cirrhotic patients had on-treatment deaths which were not related to DAAs. All 7 patients who were lost to follow-up had undetectable HCV RNA level at the last visit. The SVR12 rates were comparable in terms of baseline patient characteristics and viral decline at week 4 of treatment. In conclusion, generic SOF-based regimens are well tolerated and provide high SVR12 rates in patients with chronic HCV infection. ? 2018, The Author(s).[SDGs]SDG3antivirus agent; interferon; ribavirin; sofosbuvir; adult; aged; chronic hepatitis C; clinical trial; combination drug therapy; drug effect; female; Hepacivirus; human; liver cirrhosis; male; middle aged; multicenter study; procedures; retrospective study; Taiwan; very elderly; virology; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Taiwanjournal article10.1038/s41598-018-32060-730209349